A new antitumor antibiotic, FR900840. III. Antitumor activity against experimental tumors

• Published in: Journal of antibiotics Vol. 42; no. 4; p. 553
• Main Authors: Nishimura, M, Nakada, H, Kawamura, I, Mizota, T, Shimomura, K, Nakahara, K, Goto, T, Yamaguchi, I, Okuhara, M
• Format: Journal Article
• Language: English
• Published: Japan 1989
• Subjects: Adenocarcinoma - drug therapy; Animals; Antibiotics, Antineoplastic - therapeutic use; Carcinoma, Small Cell - drug therapy; Carcinoma, Squamous Cell - drug therapy; Female; Humans; Hydroxybutyrates - therapeutic use; Lung Neoplasms - drug therapy; Male; Mammary Neoplasms, Experimental - drug therapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasms, Experimental - drug therapy; Serine - analogs & derivatives; Serine - therapeutic use; Stomach Neoplasms - drug therapy; Tumor Cells, Cultured
• ISSN: 0021-8820
• DOI: 10.7164/antibiotics.42.553

FR900840 [2S)-2-amino-2-carboxyethyl (3R)-2-diazo-3-hydroxybutyrate), a new antibiotic with antitumor activity was isolated from the fermentation broth of Streptomyces sp. No. 8727. Its antitumor activity was examined in three mouse tumor systems and ten human tumor systems. FR900840 had no clear effect on mouse ascitic tumors, P388 and L1210, and the B16 melanoma line, but had prominent antitumor effects on several human solid tumors. Its antitumor activity against A549 human lung adenocarcinoma was stronger than those of vinblastine, doxorubicin and cisplatin. These results suggest that FR900840 may become a useful prototype antitumor drug.